{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 2090"}, "official-title": {"#tail": "\n\t", "#text": "To amend chapter V of the Federal Food, Drug, and\n\t\t  Cosmetic Act to permit provisional approval of fast track\n\t\t  products."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130522", "#text": "May 22, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and\n\t\t\t Commerce"}, "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Griffith of\n\t\t\t Virginia", "@name-id": "G000568"}, "cosponsor": [{"#tail": ", and ", "#text": "Mr.\n\t\t\t McCaul", "@name-id": "M001157"}, {"#tail": ") introduced the following bill; which was referred to\n\t\t\t the ", "#text": "Mr. Peters of\n\t\t\t California", "@name-id": "P000608"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "HFBBDE00ACF2D437BB5622FBCD461508C", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Patient Choice Act of\n\t\t\t 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HDDC8813CC43440F080FB28923D2EA4ED"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Provisional\n\t\t\t approval for fast track products"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "Section 506 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:506"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/356", "#text": "21 U.S.C. 356", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(f)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Provisional\n\t\t\t\tapproval"}, "paragraph": [{"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " determines that a drug that is designated as a fast track product\n\t\t\t\tunder this section is adequately safe (as such term is defined in\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " shall grant\n\t\t\t\tprovisional approval and the drug may be introduced into interstate commerce on\n\t\t\t\tor after the date such provisional approval is granted.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Subject to the requirements of this subsection, if the\n\t\t\t\t", "internal-xref": {"@idref": "H0F0722F9BE1D4BC08FF68A86159CDFC4", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "paragraph (2)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:2", "@proposed": "true"}, "#tail": "), the ", "#text": "\n                    ", "@legis-path": "(e)(2)"}}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                ", "@id": "H5B9CDFFA70894F7F9C16C48E14CB7D76"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", including requirements related to\u2014", "@entity-type": "act", "#text": "paragraph (3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:3", "@proposed": "true"}, "#text": "The requirements\n\t\t\t\tunder "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "informed consent;\n\t\t\t\tand"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "H1A281D2F1DBB429AA1C5848188600F77", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 505 of this\n\t\t\t\tAct or section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:505"}, "#text": "continued pursuit of safety and efficacy\n\t\t\t\tdata for purposes of gaining approval for such drug under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "HF2A6692B2DBF460092416AF843AED2DC", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H7BA3926BA6E4446C9464CE3D0BF2C5D6"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "paragraphs (4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:4", "@proposed": "true"}, {"#tail": " relating to the length of the termination of the\n\t\t\t\tprovisional approval and withdrawal of a drug subject to provisional\n\t\t\t\tapproval.", "@entity-type": "act", "#text": "(5)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:5", "@proposed": "true"}], "#text": "The rules under\n\t\t\t\t"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H78B812E222C64A17B1B337DF79A3AFB4", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Treatment of\n\t\t\t\tprovisional approval status"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505 of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": ", except that such provisional approval shall\n\t\t\t\tbe subject to the requirements of this section, including the following:", "@entity-type": "act", "#text": "section 351\n\t\t\t\tof the Public Health Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "The provisional approval of a drug under\n\t\t\t\t", "internal-xref": {"@idref": "H5B9CDFFA70894F7F9C16C48E14CB7D76", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1/sp:A", "@proposed": "true"}, "#tail": " shall be treated in the\n\t\t\t\tsame manner as approval of a drug under ", "#text": "\n                    ", "@legis-path": "(e)(1)(A)"}, "@display-inline": "yes-display-inline"}, "#text": "\n                ", "@id": "H7FE7763EAF7B40EEB9B7BC6FE18CC214"}, {"#tail": "\n            ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " grant provisional\n\t\t\t\tapproval for such drug under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"@proposed": "true", "#tail": ".", "@entity-type": "act", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1/sp:A", "#text": "\n                      ", "internal-xref": {"@idref": "H5B9CDFFA70894F7F9C16C48E14CB7D76", "#tail": "\n                    ", "#text": "subparagraph (A)", "@legis-path": "(e)(1)(A)"}}], "#text": "The sponsor of a drug that is designated as a fast track\n\t\t\t\tproduct under this section may request that the "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "header": {"#tail": "\n                  ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                  ", "@id": "H372E769F91F94DE0A4E8D814F7705408"}, {"#tail": "\n              ", "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "grant provisional\n\t\t\t\tapproval for the drug under\n\t\t\t\t", "internal-xref": {"@idref": "H5B9CDFFA70894F7F9C16C48E14CB7D76", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                      ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1/sp:A", "@proposed": "true"}, "#tail": "; or", "#text": "\n                        ", "@legis-path": "(e)(1)(A)"}}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "HA357B107E9144DAFBDD8BB686561946B", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "provide notice to\n\t\t\t\tthe sponsor of the drug that such request is denied."}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "HC5C1CC5B70104AC88DBF40BA86544200", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "header": {"#tail": "\n                  ", "#text": "Response to\n\t\t\t\trequest"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall either\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Not later than 90 days after receiving such a request,\n\t\t\t\tthe "}, "#text": "\n                  ", "@id": "H1490E7C9FF824FB7AB6D291C92BBA00F"}], "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Request for\n\t\t\t\tprovisional approval"}, "#text": "\n                ", "@id": "H2C944BDF5A70482F8E9B91B1DA1CD070"}], "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Provisional\n\t\t\t\tapproval for adequately safe fast track products"}, "#text": "\n              ", "@id": "H38F58D3381E94C01A4ABC7418ECE0781"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " determines are sufficient, is unlikely to be greater than the\n\t\t\t\tcombined direct and secondary risks of death or morbidity, as established in\n\t\t\t\tthe literature or historical data, of\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "for at least one population, the risk of\n\t\t\t\tdeath or morbidity caused directly by an adverse effect of the drug, as\n\t\t\t\tdetermined in one or more safety studies or through other data that the\n\t\t\t\t", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the disease that\n\t\t\t\tsuch drug is intended to treat; and"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "HDB38F745B8114FDEB335DA285848173F", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "existing\n\t\t\t\ttherapies (including infection) for such disease; or"}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "H8AA676B52B774C938AF738E4E4A6E087", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H306C2516BD8D4036A85073DE78D0A205"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", or designated by the ", "@entity-type": "act", "#text": "section 802(b)(1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:802/ss:b/p:1/sp:A"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", and data adequate for the approval of such marketing\n\t\t\t\tauthorization for such drug in such country have been submitted to the\n\t\t\t\t", "@entity-type": "act", "#text": "section\n\t\t\t\t802(b)(1)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:802/ss:b/p:1/sp:B"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "the drug has had a valid marketing\n\t\t\t\tauthorization, for a period of at least 4 years, by an authority in a country\n\t\t\t\tdescribed in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H53CF03AA703A43B7988F02DCFF263691", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "term": {"#tail": " means that\u2014", "#text": "adequately safe"}, "#text": "For purposes of this subsection, with respect to a drug,\n\t\t\t\tthe term "}, "#text": "\n                ", "@id": "H1706ED7AA1E140EDBE02EE7FB34D8AE2"}, {"#tail": "\n            ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may not impose any\n\t\t\t\trequirements for purposes of the safety studies or data under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and ", "@entity-type": "act", "#text": "subsections (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:a"}, {"#tail": ", respectively, of ", "@entity-type": "act", "#text": "(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:b"}], "#tail": "\n\t\t\t\t\t\t\t", "external-xref": {"#tail": " of title 21, Code of\n\t\t\t\tFederal Regulations.", "@parsable-cite": "usc/21/312", "#text": "section 312.21", "@legal-doc": "usc"}, "@display-inline": "yes-display-inline", "#text": "The ", "internal-xref": {"@idref": "H306C2516BD8D4036A85073DE78D0A205", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "subparagraph (A)(i)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:2/sp:A/cl:i", "@proposed": "true"}, "#tail": " that are in\n\t\t\t\taddition to, or different than, the requirements for studies to establish\n\t\t\t\tsafety for purposes of Phase 1 or Phase 2, as such terms are described in\n\t\t\t\t", "#text": "\n                    ", "@legis-path": "(e)(2)(A)(i)"}}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Limitation"}, "#text": "\n                ", "@id": "H44C0775E260D4BAA85645C2F34F0CC2C"}], "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Adequately safe\n\t\t\t\tdefined"}, "#text": "\n              ", "@id": "H0F0722F9BE1D4BC08FF68A86159CDFC4"}, {"#tail": "\n            ", "@id": "HAAA0792DE8464E5FA2D5B9D0EFA649E4", "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Requirements"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Provisional approval of a fast track\n\t\t\t\tproduct under this subsection shall be subject to the following\n\t\t\t\trequirements:", "@display-inline": "yes-display-inline"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "clause": [{"#tail": "\n                ", "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the individual shall be informed that the\n\t\t\t\tdrug is subject to provisional approval based on limited safety data and that\n\t\t\t\tthe efficacy of the drug has not been proven;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "#text": "\n                    ", "@id": "H565EF755D1DA4F22A86736C0D2515B49", "@commented": "no"}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the individual shall be informed of the\n\t\t\t\tknown risks of the drug and any unknown but reasonably predictable risks of the\n\t\t\t\tdrug, including, as appropriate, potential risks of death, complications, or\n\t\t\t\tinjury resulting from use of the drug, and risks related to the potential\n\t\t\t\tineffectiveness of the drug, including progression of the disease that may\n\t\t\t\tresult in death or morbidity, or the potential for the drug to accelerate or\n\t\t\t\texacerbate the disease process; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "#text": "\n                    ", "@id": "H70FF8D603032455285C4EBC74C4C3115", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or\n\t\t\t\t", "@entity-type": "act", "#text": "subclauses (I)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:23/sp:A/cl:i/scl:I", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "(II)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:23/sp:A/cl:i/scl:II", "@proposed": "true"}], "#text": "the individual\n\t\t\t\tprovides written informed consent acknowledging that individual has been\n\t\t\t\tprovided with and understands the information under "}, "enum": {"#tail": "\n                    ", "#text": "(III)"}, "#text": "\n                    ", "@id": "H87970D82F7614AD795145B9824B8C61E", "@commented": "no"}], "enum": {"#tail": "\n                  ", "#text": "(i)"}, "header": {"#tail": "\n                  ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "As a condition of provisional approval under\n\t\t\t\t", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": ", the sponsor of a drug shall\n\t\t\t\tensure that, before such drug is dispensed to an individual\u2014", "#text": "\n                      ", "@legis-path": "(e)(1)"}}, "#text": "\n                  ", "@id": "HBB9A00EDB93D4D929D2B73166F4976ED"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall issue regulations on\n\t\t\t\tthe requirements for informed consent under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The ", "internal-xref": {"@idref": "HBB9A00EDB93D4D929D2B73166F4976ED", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "act", "#text": "clause (i)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:3/sp:A/cl:i", "@proposed": "true"}, "#tail": ". Such regulations shall be\n\t\t\t\tsimilar to the requirements for informed consent for human subjects under\n\t\t\t\tsubpart B of part 50 of title 21, Code of Federal Regulations, adjusted as\n\t\t\t\tappropriate for purposes of this subsection.", "#text": "\n                      ", "@legis-path": "(e)(3)(A)(i)"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "header": {"#tail": "\n                  ", "#text": "Regulations"}, "@display-inline": "no-display-inline", "#text": "\n                  ", "@id": "H9811C0A19F544413A74C7C5A00E2257E"}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Informed\n\t\t\t\tconsent"}, "#text": "\n                ", "@id": "H51CC4A8255E14FC999C9482E7D4F5FB9", "@commented": "no"}, {"@display-inline": "no-display-inline", "#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "A sponsor of a drug that receives a provisional\n\t\t\t\tapproval under\n\t\t\t\t", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": " shall continue to diligently\n\t\t\t\tconduct appropriate studies, after such provisional approval is granted,\n\t\t\t\tto\u2014", "#text": "\n                    ", "@legis-path": "(e)(1)"}}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Pursuit of full\n\t\t\t\tapproval required"}, "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "establish that the\n\t\t\t\tdrug has an effect on a clinical endpoint or on a surrogate endpoint that is\n\t\t\t\treasonably likely to predict clinical benefit; and"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H59CE23441F1045B091490EFB6C3A392E", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": ".", "@entity-type": "act", "#text": "section 351 of the Public Health Service\n\t\t\t\tAct", "@value": "Public Health Service Act/s:351"}], "#text": "collect the data\n\t\t\t\tnecessary to demonstrate that the drug is safe and effective (or, in the case\n\t\t\t\tof a biologic, safe and potent) for purpose of obtaining approval for such drug\n\t\t\t\tunder "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "H1B972609133B480195D0E58931F150DB", "#text": "\n                  "}], "#text": "\n                ", "@id": "H69320B0C1C044C6188C6004A1F1A58AE"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"@proposed": "true", "#tail": " applies to a drug, the\n\t\t\t\tsponsor of the drug shall submit copies of all promotional materials related to\n\t\t\t\tthe drug at least 30 days prior to dissemination of the materials.", "@entity-type": "act", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "#text": "\n                    ", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "#tail": "\n                  ", "#text": "paragraph (1)", "@legis-path": "(e)(1)"}}, "#text": "During the period that provisional approval under\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n                ", "#text": "Promotional\n\t\t\t\tmaterials"}, "#text": "\n                ", "@id": "H23FFA9F103D2425687B7BB5E9974CB5D", "@commented": "no"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505 of\n\t\t\t\tthis Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": ".", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "Section 505\u20131 shall\n\t\t\t\tapply to a drug subject to provisional approval under this subsection in the\n\t\t\t\tsame manner that such section applies to a drug approved under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "header": {"#tail": "\n                  ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                  ", "@id": "H57D09234CCCF45178397ACA85A4EBE29"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " authority under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary\u2019s", "@entity-id": "7500"}, {"#tail": " to determine if a risk evaluation and mitigation strategy is\n\t\t\t\tnecessary.", "@entity-type": "act", "#text": "section 505\u20131", "@value": "Federal Food, Drug, and Cosmetic Act/s:505\u20131"}], "#text": "Nothing in this\n\t\t\t\tsubparagraph shall be construed to limit the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "header": {"#tail": "\n                  ", "#text": "Rule of\n\t\t\t\tconstruction"}, "#text": "\n                  ", "@id": "HDF9EABBDA874446BB3DDA29DD571965B"}], "enum": {"#tail": "\n                ", "#text": "(D)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Risk evaluation\n\t\t\t\tand mitigation strategy"}, "#text": "\n                ", "@id": "H44067F69A2904FAFB7B632E923A2BEDF", "@commented": "no"}, {"#tail": "\n            ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "which is related\n\t\t\t\tto the treatment of the condition with respect to which such drug was\n\t\t\t\tdesignated as a fast track product; and"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H0E66773C0A4F40ABB7FA467BAF2EF61E", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "for which the\n\t\t\t\tdrug is demonstrated to be adequately safe."}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "HC1BD7CCD033544DABD99DF231D1B1FF3", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(E)"}, "header": {"#tail": "\n                ", "#text": "Indication of\n\t\t\t\tuse"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The provisional approval under\n\t\t\t\t", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": " shall only apply to the\n\t\t\t\tindication of use for the drug\u2014", "#text": "\n                    ", "@legis-path": "(e)(1)"}}, "#text": "\n                ", "@id": "H13F5A4D4B6DC46E4B11494AA8579AF52"}], "@commented": "no"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": ".", "@entity-type": "act", "#text": "section 351 of the Public\n\t\t\t\tHealth Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "The date that the\n\t\t\t\tdrug is approved under "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "HFEA3718A74094763ACDE83B04E14497A", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "At the end of the\n\t\t\t\t5-year period beginning on the date on which provisional approval was granted\n\t\t\t\tfor such drug, except\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " determines that the\n\t\t\t\tsponsor of the drug is diligently engaging in actions (including conducting\n\t\t\t\tclinical trials) for the purpose of seeking approval under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of\n\t\t\t\tthis Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": " (excluding provisional\n\t\t\t\tapproval under\n\t\t\t\t", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, {"#tail": " determines\n\t\t\t\tthat the sponsor requires additional time to complete such actions and attain\n\t\t\t\tsuch approval, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may extend such period for an appropriate length\n\t\t\t\tof time to allow the sponsor to complete such actions and attain such approval;\n\t\t\t\tor", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "if the ", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                      ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": ") and the ", "#text": "\n                        ", "@legis-path": "(e)(1)"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "H1175B6DBEF49473393BDF627EB0546AE", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " determines that the\n\t\t\t\ttermination of the provisional approval is adverse to protecting or promoting\n\t\t\t\tthe public health, the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may extend such period for an appropriate\n\t\t\t\tlength of time to protect or promote the public health.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "if the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "H35BF8104F6B24D11A4D8AC53DA0D9B2D", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H0ABD7D6BE3324F94A265F601E50E3ABD"}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the provisional approval of the drug\n\t\t\t\tunder\n\t\t\t\t", "@entity-type": "act", "#text": "section 526", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, "#text": "In the case of a drug\n\t\t\t\tthat is not designated under ", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": " shall terminate on the\n\t\t\t\tearlier of the following:", "#text": "\n                    ", "@legis-path": "(e)(1)"}, "@display-inline": "yes-display-inline"}, "#text": "\n                ", "@id": "HB70BB2DE3D3049E686E0242D9A640298"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ",\n\t\t\t\tthe provisional approval of the drug under\n\t\t\t\t", "@entity-type": "act", "#text": "section 526", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": ".", "@entity-type": "act", "#text": "section 351 of\n\t\t\t\tthe Public Health Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "In the case of a drug designated under ", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": " shall terminate on the date\n\t\t\t\tthat the drug is approved under ", "#text": "\n                    ", "@legis-path": "(e)(1)"}}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Special rule for\n\t\t\t\torphan drugs"}, "#text": "\n                ", "@id": "H9179E2F506C94D29986AC19F6E9D144B"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "quote": {"#tail": " shall not be construed to include a provisional\n\t\t\t\tapproval under\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": "\n                  ", "@entity-type": "act", "#text": "section 351 of the Public\n\t\t\t\tHealth Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "approved under "}, "#text": "For purposes of this paragraph, the phrase\n\t\t\t\t", "internal-xref": {"@idref": "H38F58D3381E94C01A4ABC7418ECE0781", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:1", "@proposed": "true"}, "#tail": "\n                ", "#text": "\n                    ", "@legis-path": "(e)(1)"}}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "header": {"#tail": "\n                ", "#text": "Rule of\n\t\t\t\tconstruction"}, "#text": "\n                ", "@id": "H5E5AD7D568434D4EA39B9D83781702BB"}], "enum": {"#tail": "\n              ", "#text": "(4)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Termination of\n\t\t\t\tprovisional approval"}, "#text": "\n              ", "@id": "H80B0EAB233244A72830C532C9E25159D"}, {"#tail": "\n            ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tshall apply to a drug subject to a provisional approval under this subsection\n\t\t\t\tin the same manner as such subsection applies to any fast track product.", "@entity-type": "act", "#text": "Subsection (b)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:b/p:3"}, "#text": "\n                  ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                ", "@id": "HBAEF26191DD344FAA2D3EF7F9E7D4F4F"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may\n\t\t\t\twithdraw approval of a fast track product using the expedited procedures\n\t\t\t\tapplied under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " if the requirements of ", "@entity-type": "act", "#text": "subsection (b)(3)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:b/p:3"}, {"#tail": " have\n\t\t\t\tnot been met with respect to the drug.", "@entity-type": "act", "#text": "paragraph (3)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:3/sp:A", "@proposed": "true"}], "#text": "In\n\t\t\t\taddition to\n\t\t\t\t", "internal-xref": {"@idref": "H6ADE5D98F9C340C892F61FA7A62634E5", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:5/sp:A", "@proposed": "true"}, "#tail": ", the ", "#text": "\n                    ", "@legis-path": "(e)(6)(A)"}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Additional\n\t\t\t\twithdrawal authority"}, "#text": "\n                ", "@id": "H3EC65FA7A82A4375B6626C2FCDFCA459"}], "enum": {"#tail": "\n              ", "#text": "(5)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Withdrawal"}, "#text": "\n              ", "@id": "H05D62D36439E4117AE52BDEAF5889D60"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", ", "@entity-type": "act", "#text": "sections 505(c)(3)(E)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:E"}, {"#tail": ", ", "@entity-type": "act", "#text": "505(j)(5)(F)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F"}, {"#tail": ", and ", "@entity-type": "act", "#text": "505A", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": " shall apply to a drug\n\t\t\t\tsubject to provisional approval under this subsection in the same manner that\n\t\t\t\tsuch rules apply to drugs approved under ", "@entity-type": "act", "#text": "527", "@value": "Federal Food, Drug, and Cosmetic Act/s:527"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505 of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": ", except that the period of provisional\n\t\t\t\tapproval under this subsection for a drug shall be an addition to the\n\t\t\t\tapplicable period of marketing exclusivity for such\n\t\t\t\tdrug.", "@entity-type": "act", "#text": "section 351\n\t\t\t\tof the Public Health Service Act", "@value": "Public Health Service Act/s:351"}], "#text": "The rules related to marketing exclusivity\n\t\t\t\tunder "}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "header": {"#tail": "\n              ", "#text": "Impact on\n\t\t\t\tmarketing exclusivity"}, "#text": "\n              ", "@id": "H6ADE5D98F9C340C892F61FA7A62634E5"}], "#text": "\n            ", "@id": "H69BF20B5813C4F5CA086DAB57DC4F0A9"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "H0A9685A14DD54CAE8E4A12B3D2B6876A"}, "#text": "\n        ", "@id": "H6F18171B511A417EBDFE4D24D13A7E82"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by adding at the end the following:", "@entity-type": "act", "#text": "Section 502 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:502"}, "#text": "\n          ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Misbranding for\n\t\t\t marketing of terminated drug"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ",\n\t\t\t\tunless, on or before the date such drug is so introduced or delivered, such\n\t\t\t\tdrug is approved under ", "@entity-type": "act", "#text": "section 506(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f", "@proposed": "true"}, {"#tail": " or ", "@entity-type": "act", "#text": "section 505(c) of this Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:c"}, {"#tail": ".", "@entity-type": "act", "#text": "section 351 of the Public\n\t\t\t\tHealth Service\n\t\t\t\tAct", "@value": "Public Health Service Act/s:351"}], "#text": "If it is a drug that is introduced or\n\t\t\t\tdelivered for introduction into interstate commerce after the date of the\n\t\t\t\ttermination of the provisional approval for such drug under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(bb)"}, "@id": "H7892FABF288043548351042CBE1518CC", "#text": "\n            "}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "HA0F8134A024C44DF97BDE666B903FCCB"}, "#text": "\n        ", "@id": "HB19B289776A5425C90422EC50CD9AEFD"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is further\n\t\t\t amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "chapter V of\n\t\t\t the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:V"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "@parsable-cite": "usc/21/351", "#text": "21 U.S.C. 351", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Conforming\n\t\t\t amendments"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",\n\t\t\t by inserting ", "@entity-type": "act", "#text": "section 502(a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:502/ss:a"}, "#text": "in ", "quote": [{"#tail": " after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ")", "@entity-type": "act", "#text": "section 506(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f", "@proposed": "true"}, "#text": "(or an indication subject to a provisional approval under\n\t\t\t "}, {"#tail": ";", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "\n\t\t\t or under ", "@entity-type": "act", "#text": "section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, {"#tail": "\n            ", "@entity-type": "act", "#text": "section 351(a) of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}], "#text": "an indication approved under "}]}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H4F03F6E1235D4874A66F2FDF1EA1888B", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "section\n\t\t\t 506A", "@value": "Federal Food, Drug, and Cosmetic Act/s:506A"}, "#text": "in "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "#text": "\n          ", "@id": "HD2E0F816BD57471BBF6C03242F20E8A0", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",\n\t\t\t by inserting ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506A/ss:a"}, "#text": "in ", "quote": [{"#tail": "\n\t\t\t after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ")", "@entity-type": "act", "#text": "section 506(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f", "@proposed": "true"}, "#text": "(or a provisional approval under "}, {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "section 351 of the Public Health Service\n\t\t\t Act", "@value": "Public Health Service Act/s:351"}, "#text": "a license under "}]}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "HFBAF59C02A62402ABD0B78FCF7D31921", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "by adding at the\n\t\t\t end the following:"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": ";"}, "#tail": "\n\t\t\t\t\t", "subsection": {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", any reference to safety and efficacy\n\t\t\t\tunder this section shall be treated as a reference to adequate safety, as such\n\t\t\t\tterm is defined for purposes of such ", "@entity-type": "act", "#text": "section 506(f)", "@value": "Public Health Service Act/s:506/ss:f", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "section\n\t\t\t\t506(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f", "@proposed": "true"}], "#text": "In the case of a drug subject to a\n\t\t\t\tprovisional approval under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(e)"}, "header": {"#tail": "\n                ", "#text": "Special rule for\n\t\t\t\tdrugs subject to provisional approval"}, "#text": "\n                ", "@id": "H022AA14E6B5C4ED49977F4455F5EC4F5"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t\t", "@id": "H05EA4947D1F94F8CBADECC7091151296"}, "#text": "\n            ", "@id": "HA5971A373B404C5381618D84387D7066"}]}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by adding at the end the following:", "@entity-type": "act", "#text": "section\n\t\t\t 506B(a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506B/ss:a"}, "#text": "in "}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": ";\n\t\t\t\tand"}, "#tail": "\n\t\t\t\t", "paragraph": {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit the reports required under this section on the studies\n\t\t\t\tconducted on such drug that are described in ", "@entity-type": "act", "#text": "section\n\t\t\t\t506(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f", "@proposed": "true"}, {"#tail": ". For purposes\n\t\t\t\tof this section, such reports shall be treated as reports on postmarketing\n\t\t\t\tstudies described in ", "@entity-type": "act", "#text": "section 506(f)(3)(B)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f/p:3/sp:B", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506B/ss:a/p:1"}], "#text": "A\n\t\t\t\tsponsor of a drug that is subject to a provisional approval under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Special rule for\n\t\t\t\tprovisional approval"}, "#text": "\n              ", "@id": "H2DB3FEDEA31449BAADABAD704B169EA6"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "@id": "H5DFA5DA9D4DC4BCFA07DB2815ED314B0"}, "#text": "\n          ", "@id": "H483A625858764904A3084316706BACC8", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " by inserting ", "@entity-type": "act", "#text": "section\n\t\t\t 551(b)(1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:551/ss:b/p:1/sp:A"}, "#text": "in ", "quote": [{"#tail": " after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ")", "@entity-type": "act", "#text": "section\n\t\t\t 506(f)", "@value": "Federal Food, Drug, and Cosmetic Act/s:506/ss:f", "@proposed": "true"}, "#text": "(or a provisional approval under "}, {"#tail": ".", "#text": "Public Health Service Act"}]}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "H951AA7F164634B6CBB5F8566ADDAA7CC", "#text": "\n          "}], "#text": "\n        ", "@id": "H88F9CA1CFADF48DDAFFE26F1C181D2CF"}], "#text": "\n      ", "@id": "H7CA6E6BCB5C14132B0B61E78B6433DE5"}], "#text": "\n\t\t", "@id": "HCC9E445C0B2244A2AECABDD9C46458FE"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-05-22"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 2090 IH: Patient Choice Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}